Dr Mohammad Afshar (Tersan CEO) is presenting on the analysis of Phase 2a trial results using Tersan’s KEM® artificial intelligence platform at CTAD 2017 (10th Clinical Trials on Alzheimer’s Disease) in Boston, USA on 4 November.
LB18 – Clinical Pharmacokinetics and Pharmacodynamics Characterization of ANAVEX™2-73 for Designing a Phase 2/3 Study in Mild-to-Moderate Alzheimer’s Disease
Mohammad Afshar, MD, PhD[1], Frédéric Parmentier, PhD[1], Ene I Ette, PhD[2], Emmanuel O Fadiran, PhD[3], Christopher U Missling, PhD[3]
[1]Tersan Pharmaceuticals Ltd, Paris, France, [2]Anoixis Corp., Natick, MA, [3]Anavex Life Sciences Corp., New York, NY
Links: |